论文已发表
注册即可获取德孚的最新动态
IF 收录期刊
APOE ϵ4 等位基因与阿尔茨海默氏病患者临床前阶段 CSF VILIP-1 水平升高相关
Authors Wang L, Zhang M, Wang Q, Jiang X, Li K, Liu J
Received 21 October 2019
Accepted for publication 21 March 2020
Published 8 April 2020 Volume 2020:16 Pages 923—931
DOI https://doi.org/10.2147/NDT.S235395
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 2
Editor who approved publication: Professor Jun Chen
Objectives: Cerebrospinal fluid (CSF) visinin-like protein 1 (VILIP-1) has been suggested as a biomarker for neuron injury, which has been shown to have a important diagnostic value in symptomatic Alzheimer’s disease (AD). The study purpose is investigating potential effects of apolipoprotein E (APOE) ϵ4 on CSF VILIP-1 levels among the preclinical AD.
Methods: A total of 110 subjects (including 43 APOE ϵ4 carriers and 67 ϵ4 non-carriers) were obtained from the Alzheimer’s Disease Neuroimaging Initiative (ADNI) in the present study.
Results: The results showed that VILIP-1 concentrations in the CSF were statistically significantly increased in APOE ϵ4 carriers in comparison with non-carriers. Increased CSF VILIP-1 level was positively associated with the concentrations of both CSF-tau and P-tau levels.
Conclusions: Our findings suggested that APOE ϵ4 might affect CSF VILIP-1 level in preclinical AD, indicating an important role of APOE ϵ4 in neuron injury leading to AD.
Keywords: APOE ϵ4, VILIP-1, Alzheimer’s disease, cerebrospinal fluid
